Pharmacogenetic studies of epilepsy drugs: are we there yet?

Trends in Genetics

Volumn 22, Issue 5, 2006, Pages 250-252

  Spurr, Nigel K ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLYCOPROTEIN P; PHENYTOIN; VOLTAGE GATED SODIUM CHANNEL;

BLOOD BRAIN BARRIER; DRUG METABOLISM; DRUG TARGETING; EPILEPSY; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE DISRUPTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAXIMUM TOLERATED DOSE; MEDICAL DOCUMENTATION; PHARMACOGENETICS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; DOSE RESPONSE; DRUG THERAPY; GENETIC POLYMORPHISM; METHODOLOGY; REVIEW;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; EPILEPSY; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 33745874395     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2006.03.004     Document Type: Short Survey

References (6)

1. Roses A.D. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 5 (2004) 645-656
2. Kirchheiner J., et al. Pharmacogenetics-based therapeutic recommendations ready for clinical practice?. Nat. Rev. Drug Discov. 4 (2005) 639-647
3. Tate S.K., et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl. Acad. Sci. 102 (2005) 5507-5512
4. Soranzo N., et al. The role of common variation in drug transporter genes in refractory epilepsy. Expert Opin. Pharmacother. 6 (2005) 1305-1312
5. Szoeke C.E., et al. Update on pharmacogenetics in epilepsy: a brief review. Lancet Neurol. 5 (2006) 189-196
6. Escayg A., et al. A novel SCNA1 mutation associated with generalized epilepsy with febrile seizures plus- prevalence of variants in patients with epilepsy. Am. J. Hum. Genet. 68 (2001) 866-873